Integrated multi-omics analyses have identified IDO1 as a co-expression partner of PD-1 on tumor-associated macrophages, underscoring its utility as both a prognostic biomarker and a promising immunotherapeutic target in ESCC (74). The gene discussed is IDO1; the disease is esophageal squamous cell carcinoma.